Alnylam Elects Amy Schulman to its Board of Directors

  Alnylam Elects Amy Schulman to its Board of Directors

– Appointment of Industry Leader Brings Broad Strategic, Commercial, and Legal
                            Experience to Board –

Business Wire

CAMBRIDGE, Mass. -- July 2, 2014

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today the election of Amy W. Schulman to its Board of
Directors. Ms. Schulman is the former Executive Vice President and General
Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer’s
Consumer Healthcare business. She currently serves on the faculty of Harvard
Business School as a Senior Lecturer.

“Amy is a recognized leader in the development and growth of global
pharmaceutical businesses, and she will bring this expertise to our Board as
we continue to build Alnylam as a leading biotechnology company. As the former
General Counsel at Pfizer, Amy also brings deep legal expertise to our Board,”
said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “Given our
robust clinical progress and our potential transition to a commercial company
in the coming years, Amy’s addition to our Board comes at an opportune time as
we advance RNAi therapeutics to patients.”

“I am excited to join the Board of Alnylam, a first-in-class innovation-based
biotechnology company, and a pioneer in advancing an entirely new class of
high impact medicines with RNAi therapeutics,” said Ms. Schulman. “The
tremendous progress Alnylam has made in its clinical efforts has yielded very
encouraging results. I look forward to working with the outstanding team of
management and directors in place today and contributing to the company’s
value creation strategy and execution.”

Ms. Schulman originally joined Pfizer in 2008 as General Counsel and saw the
company through its $68 billion acquisition of Wyeth. In 2010, in addition to
her role as General Counsel, Ms. Schulman became President and General Manager
of Pfizer’s $2.1 billion global infant formula and nutrition business. Once
that business was sold to Nestlé she assumed responsibility for the Consumer
Healthcare business. Before joining Pfizer, she was a partner at DLA Piper,
where she was a member of the Board and Executive Policy Committees, and built
and led the international law firm’s mass tort and class-action practice. Ms.
Schulman’s accomplishments have earned her recognition from leading
publications and organizations. In 2013 Fortune magazine named her one of the
“50 Most Powerful Women in Business.” That same year, The American Lawyer
named her one of the “Top 50 Innovators,” and The National Law Journal named
her one of “The 100 Most Influential Lawyers in America.” The American Bar
Association honored her with the Margaret Brent Women Lawyers of Achievement
award in 2012. A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman
earned her J.D. from Yale Law School in 1989. She serves on the Board of
Directors of The Brookings Institution and Wesleyan University.

About RNAi

RNAi (RNA interference) is a revolution in biology, representing a
breakthrough in understanding how genes are turned on and off in cells, and a
completely new approach to drug discovery and development. Its discovery has
been heralded as “a major scientific breakthrough that happens once every
decade or so,” and represents one of the most promising and rapidly advancing
frontiers in biology and drug discovery today which was awarded the 2006 Nobel
Prize for Physiology or Medicine. RNAi is a natural process of gene silencing
that occurs in organisms ranging from plants to mammals. By harnessing the
natural biological process of RNAi occurring in our cells, the creation of a
major new class of medicines, known as RNAi therapeutics, is on the horizon.
Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise
Alnylam’s RNAi therapeutic platform, target the cause of diseases by potently
silencing specific mRNAs, thereby preventing disease-causing proteins from
being made. RNAi therapeutics have the potential to treat disease and help
patients in a fundamentally new way.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation of RNAi as a
new class of innovative medicines with a core focus on RNAi therapeutics as
genetic medicines, including programs as part of the company’s “Alnylam
5x15^TM” product strategy. Alnylam’s genetic medicine programs are RNAi
therapeutics directed toward genetically defined targets for the treatment of
serious, life-threatening diseases with limited treatment options for patients
and their caregivers. These include: patisiran (ALN-TTR02), an intravenously
delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of
TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic
polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic
targeting TTR for the treatment of ATTR in patients with TTR cardiac
amyloidosis, including familial amyloidotic cardiomyopathy (FAC) and senile
systemic amyloidosis (SSA); ALN-AT3, an RNAi therapeutic targeting
antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders
(RBD); ALN-CC5, an RNAi therapeutic targeting complement component C5 for the
treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic
targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic
porphyrias including acute intermittent porphyria (AIP); ALN-PCS, an RNAi
therapeutic targeting PCSK9 for the treatment of hypercholesterolemia;
ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the
treatment of AAT deficiency-associated liver disease; ALN-TMP, an RNAi
therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and
iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting
angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed
hyperlipidemia and severe hypertriglyceridemia; ALN-AC3, an RNAi therapeutic
targeting apolipoprotein C-III (apoCIII) for the treatment of
hypertriglyceridemia; and other programs yet to be disclosed. As part of its
“Alnylam 5x15” strategy, as updated in early 2014, the company expects to have
six to seven genetic medicine product candidates in clinical development -
including at least two programs in Phase 3 and five to six programs with human
proof of concept - by the end of 2015. Alnylam is also developing ALN-HBV, an
RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the
treatment of HBV infection. The company’s demonstrated commitment to RNAi
therapeutics has enabled it to form major alliances with leading companies
including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko
Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and
Genzyme, a Sanofi company. In March 2014, Alnylam acquired Sirna Therapeutics,
a wholly owned subsidiary of Merck. In addition, Alnylam holds an equity
position in Regulus Therapeutics Inc., a company focused on discovery,
development, and commercialization of microRNA therapeutics. Alnylam
scientists and collaborators have published their research on RNAi
therapeutics in over 200 peer-reviewed papers, including many in the world’s
top scientific journals such as Nature, Nature Medicine, Nature Biotechnology,
Cell, the New England Journal of Medicine, and The Lancet. Founded in 2002,
Alnylam maintains headquarters in Cambridge, Massachusetts. For more
information, please visit

Alnylam Forward-Looking Statements

Various statements in this release concerning Alnylam’s future expectations,
plans and prospects, including without limitation, Alnylam’s views with
respect to the potential for RNAi therapeutics, its expectations regarding its
“Alnylam 5x15” product strategy, and its plans regarding commercialization of
RNAi therapeutics, constitute forward-looking statements for the purposes of
the safe harbor provisions under The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including, without limitation, Alnylam’s ability to manage operating expenses,
Alnylam’s ability to discover and develop novel drug candidates and delivery
approaches, successfully demonstrate the efficacy and safety of its drug
candidates, the pre-clinical and clinical results for its product candidates,
which may not support further development of product candidates, actions of
regulatory agencies, which may affect the initiation, timing and progress of
clinical trials, obtaining, maintaining and protecting intellectual property,
Alnylam’s ability to enforce its patents against infringers and defend its
patent portfolio against challenges from third parties, obtaining regulatory
approval for products, competition from others using technology similar to
Alnylam’s and others developing products for similar uses, Alnylam’s ability
to obtain additional funding to support its business activities and establish
and maintain strategic business alliances and new business initiatives,
Alnylam’s dependence on third parties for development, manufacture, marketing,
sales and distribution of products, the outcome of litigation, and unexpected
expenditures, as well as those risks more fully discussed in the “Risk
Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission (SEC) and in other filings that
Alnylam makes with the SEC. In addition, any forward-looking statements
represent Alnylam’s views only as of today and should not be relied upon as
representing its views as of any subsequent date. Alnylam explicitly disclaims
any obligation to update any forward-looking statements.


Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
Vice President, Investor Relations and
Corporate Communications
Liz Bryan, 202-955-6222 x2526
Press spacebar to pause and continue. Press esc to stop.